UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934
Date of Report (Date of earliest reported): December 31, 2014
MANHATTAN SCIENTIFICS, INC.
(Exact name of registrant as specified in charter)
Delaware |
|
000-28411 |
|
85-0460639 |
(State or Other Jurisdiction of Incorporation or Organization) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
The Chrysler Building
405 Lexington Avenue, 26th Floor
New York, New York, 10174
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, including area code: (212) 541-2405
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On Decemebr 30, 2014, Manhattan Scientifics Inc. (the ”Company”) released a press release relating to the expansion of the executive team of Senior Scientifics LLC (”Senior”), a wholly owned subsidiary of the Company, including the planned appointment of a new COO/President. On December 31, 2014, Gerald Grafe resigned as President of Senior. Mr. Grafe will remain with Senior focusing on strategic relationships and intellectual property issues.
Item 9.01 Financial Statements and Exhibits
Exhibit No. |
Description of Exhibit |
|
99.1 |
Press Release dated December 30, 2014 |
2
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MANHATTAN SCIENTIFICS, INC. |
|||
Date: January 5, 2015 |
By: | /s/ Emmanuel Tsoupanarias | |
New York, New York | Name: | Emmanuel Tsoupanarias | |
Title: | Chief Executive Officer |
3
EXHIBIT 99.1
Manhattan Scientifics Announces Expansion of Executive Team at Its Senior Scientific Subsidiary
Dec 30, 2014
OTC Disclosure & News Service
Manhattan Scientifics, Inc. (OTCQB:MHTX) is recruiting a seasoned executive to oversee Senior Scientific’s next stage of product development for its MRX diagnostic technology for the early detection of cancer. The new President and COO candidate under consideration, has a strong background in the life sciences and experience in diagnostic medical product development. The new President/COO will be responsible for expanding the collaborations in place with the MD Anderson Cancer Center in Houston and The University of New Mexico Health Sciences Center, Albuquerque, to help further develop this technology.
Additional details will be made public when the contract is finalized and executed. Gerald Grafe, current president of Senior Scientific, will remain with the Company to focus on strategic relationships and intellectual property issues. Edward R. Flynn, PhD, founder of Senior Scientific, will remain as Chief Scientist.
Gerald Grafe, current president of Senior Scientific, said, “The time has come to expand our business from early stages of technology development to demonstrating the ultimate value. For this, we need the leadership of an experienced executive with a history of accomplishment in medical market product development. Fortunately, we have identified an excellent candidate, and we expect to be able to announce his appointment in the near future.”
Manny Tsoupanarias, CEO of Manhattan Scientifics, said, “We are grateful for the leadership that Gerald Grafe has given Senior Scientific over the past several years. He has moved the Company significantly forward in a number of critical areas. We are pleased that he will remain a key member of the team as we seek to move into a new stage of development. We believe the Company’s future is highly promising and we are quite excited about our future."
Marvin Maslow, founder of Manhattan Scientifics, said, “Over the past few years, Gerald and Dr. Flynn have provided the leadership to build on Dr. Flynn’s serious foundation work, establishing the Company’s technology base with nanoparticle manufacturing and multiple instruments; our collaboration with MD Anderson and the UNM Health Sciences Center and Cancer Center, including the delivery of an MRX diagnostic instrument; our ever-expanding intellectual property portfolio; and our interaction with early investors. We look forward to updating investors about our new president and COO."
About Manhattan Scientifics, Inc.
Manhattan Scientifics Inc. is located in New Mexico, New York and Montreal, is focused on the commercialization of disruptive technologies in the nano-medicine space. It has achieved several critical milestones in the development of its proprietary technology for the very early detection of cancer. The company is also at work with its licensed NYSE "partner" to commercialize medical prosthetics applications for its patented ultra-fine-grain nanotechnology metals.
About Senior Scientific LLC
Senior Scientific, LLC (www.seniorscientific.com) is a New Mexico Company with research facilities located at the University of New Mexico Science and Technology Park in Albuquerque, New Mexico and longstanding relationships with the University of New Mexico Health Sciences Center, the Los Alamos National Laboratories, and the Center for Integrated Nanotechnology (CINT) at Sandia National Laboratory. The Company’s focus is in the emerging field of molecular imaging and nanobiotechnology for the early detection and localization of cancer and other human diseases, and is the leader in a technology called Nanomagnetic Relaxometry. Its proprietary technologies and methods employ magnetic nanoparticles targeted towards cells associated with cancer and other diseases, and detect those cells tagged with magnetic nanoparticles through sophisticated magnetic sensors.
Forward-looking statement
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.